Abstract
Acetylator phenotype has been determined using sulfamethazine in 109 patients histologically diagnosed with colorectal carcinoma (resected in 74 patients by the time of the study) and in 96 age-matched controls.
Fifty-five % of patients and 58.3% of controls were classified as slow acetylators (χ2 = 0.11, not significant). No differences were observed in the distribution of acetylator phenotype when analyzing separately male and female, surgically treated and untreated, and colonic and rectal carcinoma patients.
We conclude that acetylator polymorphism is not a genetic trait related to the risk of developing colorectal carcinoma in human beings.
Footnotes
-
↵1 Supported by Grant CICYT PB86-0672 of the Dirección General de Promoción de la Investigación, Spain.
-
↵2 To whom requests for reprints should be addressed, at C/Modesto Lafuente 46, 5° C, 28003 Madrid, Spain.
- Received October 9, 1990.
- Accepted January 31, 1991.
- ©1991 American Association for Cancer Research.
Volume 51, Issue 8
